12 reports

AFREZZA COMES WITH A BOXED WARNING ABOUT THE RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH ASTHMA AND CHRONIC LUNG DISEASE, WHICH MIGHT LIMIT ITS WIDESPREAD USE.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Sanofi S.A.

AFREZZA COMES WITH A BOXED WARNING ABOUT THE RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH ASTHMA AND CHRONIC LUNG DISEASE, WHICH MIGHT LIMIT ITS WIDESPREAD USE.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

AFREZZA COMES WITH A BOXED WARNING ABOUT THE RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH ASTHMA AND CHRONIC LUNG DISEASE, WHICH MIGHT LIMIT ITS WIDESPREAD USE.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

AFREZZA COMES WITH A BOXED WARNING ABOUT THE RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH ASTHMA AND CHRONIC LUNG DISEASE, WHICH MIGHT LIMIT ITS WIDESPREAD USE.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

AFREZZA COMES WITH A BOXED WARNING ABOUT THE RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH ASTHMA AND CHRONIC LUNG DISEASE, WHICH MIGHT LIMIT ITS WIDESPREAD USE.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group
  • Business Description
  • VENTURE FINANCING

It also performs clinical trials and tolerance assay studies in transplantation, autoimmune diseases, and allergy and asthma.

  • Diabetes
  • Pharmaceutical
  • Type 1 Diabetes
  • United States
  • GlobalData's company

a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that preclinical data from three programs using the company' s XmAb bispecific Fc technology show that

  • Diabetes
  • Type 1 Diabetes
  • United States
  • Product Initiative
  • Xencor, Inc.
  • TYPE 1 DIABETES (JUVENILE DIABETES) - PIPELINE BY SELECTA BIOSCIENCES, INC., H2 2016
  • TYPE 1 DIABETES (JUVENILE DIABETES) - PIPELINE BY SEMMA THERAPEUTICS INC., H2 2016

Its pharmaceutical products comprise inhaled corticosteroid for asthma, osteoporosis drugs, anti-hyperuricemia agent, and others.

  • Biotechnology
  • Type 1 Diabetes
  • Company
  • Product Initiative
  • AstraZeneca PLC
  • Research and Development Brief
  • INV-88 - DRUG PROFILE

Centocor, Inc. initiated two Phase II trials of golimumab in treating asthma patients.

  • Cell Therapy
  • Type 1 Diabetes
  • United States
  • Company
  • Product Initiative
  • SFC FLUIDICS ENTERS INTO DEVELOPMENT PARTNERSHIP WITH JUVENILE DIABETES RESEARCH FOUNDATION
  • PARTNERSHIPS

It also performs clinical trials and tolerance assay studies in transplantation, autoimmune diseases, and allergy and asthma.

  • Chronic Disease
  • Diabetes
  • Type 1 Diabetes
  • United States
  • GlobalData's company
  • Research and Development Brief
  • INV-88 - DRUG PROFILE

Centocor, Inc. initiated two Phase II trials of golimumab in treating asthma patients.

  • Chronic Disease
  • Type 1 Diabetes
  • United States
  • Company
  • Product Initiative

IT DEVELOPS INHALATION PRODUCTS, TO HELP PATIENTS SUFFERING FROM AIRWAYS DISEASES SUCH AS ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CYSTIC FIBROSIS, PULMONARY FIBROSIS AND OTHER DISEASES.

  • Endocrine Disease
  • Therapy
  • Type 1 Diabetes
  • United States
  • Product Initiative